• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: GridAI Technologies Corp. filed SEC Form 8-K: Financial Statements and Exhibits

    4/13/26 6:01:19 AM ET
    $GRDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GRDX alert in real time by email
    false 0001604191 0001604191 2025-09-30 2025-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K/A

    (Amendment No. 1)

     

     

     

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): September 30, 2025

     

     

     

    GridAI Technologies Corp.
    (Exact name of Registrant as Specified in its Charter)

     

     

     

    Delaware   001-37853   46-4993860
    (State or other Jurisdiction of
    Incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

      

    777 Yamato Road, Suite 502
    Boca Raton, FL   33431

    (Address of Principal Executive Offices)   (Zip Code)

     

     

     

    (561) 589-5444

    (Registrant’s Telephone Number, Including Area Code)

     

    N/A

    (Former name or former address, if changed since last report.)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class   Trading Symbol(s)  

    Name of each exchange on which
    registered

    Common Stock, par value $0.0001 per share   GRDX   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    On October 6, 2025, GridAI Technologies Corp. (f/k/a Entero Therapeutics, Inc.), a Delaware corporation (the “Company” or “we”), filed a Current Report on Form 8-K (the “Initial 8-K”) disclosing, amongst other things, the completion of its previously announced share exchange agreement (the “Share Exchange Agreement”) with GridAI Corp, a Nevada corporation (“GridAI”), and the stockholders of all of the issued and outstanding shares of GridAI.

     

    The Company is amending the Initial 8-K to include [certain risk factors related to GridAI’s business and consummation of the transactions contemplated by the Share Exchange Agreement (the “Risk Factors”), an overview of GridAI’s business (the “Business Section”),] historical financial statements of GridAI and the unaudited pro forma combined financial information giving effect to the Share Exchange Agreement as of September 30, 2025.

     

    The pro forma financial information included herein has been presented for informational purposes only. It does not purport to represent the actual results of operations that we and GridAI would have achieved had the companies been combined during the periods presented in the pro forma financial information and is not intended to project the future results of operations that the combined company may achieve.

     

    The Business Section and Risk Factors are filed as Exhibit 99.3 to this Current Report on Form 8-K/A and are incorporated herein by reference.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (a) Pro Forma Financial Information.

     

    The unaudited pro forma condensed combined balance sheet as of September 30, 2025 and the unaudited pro forma condensed combined statement of operations for the nine months ended September 30, 2025 are filed with this Current Report on Form 8-K/A as Exhibit 99.2 and incorporated herein by reference.

     

    (b) Financial Statements of Businesses Acquired.

     

    The audited financial statements of GridAI from inception to September 30, 2025 are filed as Exhibit 99.1 to this Current Report on Form 8-K/A and incorporated herein by reference.

     

    (c) Exhibits.

     

    No.   Description
    23.1   Consent of Macias Gini & O’Connell LLP
    99.1   Audited Financial Statements of GridAI Corp. as of September 30, 2025
    99.2   Unaudited Pro Forma Condensed Combined Balance Sheet. as of September 30, 2025 and the Unaudited Pro Forma Condensed Combined Statement of Operations for the period ended September 30, 2025
    99.3   Business Section and Risk Factors
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    GRIDAI TECHNOLOGIES CORP.

       

    Date: April 13, 2026

    By: /s/ Jason D. Sawyer
      Name:  Jason D. Sawyer
      Title: Chief Executive Officer

     

     

    Get the next $GRDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GRDX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GRDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Powell Max Limited Successfully Repositions for Its Next Phase of Growth

    Hong Kong, TX, March 09, 2026 (GLOBE NEWSWIRE) -- Powell Max Limited (NASDAQ:PMAX) ("Powell Max" or the "Company"), a financial communications services provider, is pleased to provide the following corporate update regarding its successful repositioning. Key Highlights: Raised $17 million in capital from new investorsAppointed new Chairman and Chief Executive Officer Geordan PursgloveReconstituted the Board of DirectorsRegained compliance with Nasdaq listing requirements Powell Max Chairman and Chief Executive Officer Geordan Pursglove commented, "My first month at Powell Max has been extremely productive. We successfully completed a corporate restructuring in a short timeframe, raised

    3/9/26 8:30:00 AM ET
    $ALBT
    $CISO
    $GRDX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Professional Services
    Consumer Discretionary

    IBN Announces Latest Episode of The TechMediaWire Podcast featuring Marshall Chapin, CEO of Grid AI Corp.

    AUSTIN, Texas, March 05, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The TechMediaWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The TechMediaWire Podcast delivers informative updates and exclusive interviews with executives operating in the tech industry. The TechMediaWire Podcast's latest episode features Marshall Chapin, CEO of Grid AI Corp., wholly-owned by GridAI Technologies Corp. (NASDAQ:GRDX), a technology company focused on intelligent en

    3/5/26 8:00:00 AM ET
    $GRDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GridAI Technologies Corp. Appoints Veteran Energy Executive Tim Healy as Executive Chairman of Grid AI Corp.

    BOCA RATON, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- via IBN – GridAI Technologies Corp. (NASDAQ:GRDX), a technology company focused on intelligent energy orchestration for hyperscale AI data centers, today announced the appointment of Tim Healy as Executive Chairman of the Board of Grid AI Corp., the Company's wholly owned operating subsidiary. Healy brings more than two decades of experience as a founder, CEO, board leader, and investor across the energy technology and energy transition landscape. Over his career, he has founded multiple public companies, establishing a track record of scaling innovative platforms from early commercialization through global deployment and strategic exits

    2/4/26 8:00:00 AM ET
    $GRDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRDX
    SEC Filings

    View All

    Amendment: GridAI Technologies Corp. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K/A - GridAI Technologies Corp. (0001604191) (Filer)

    4/13/26 6:01:19 AM ET
    $GRDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 10-K filed by GridAI Technologies Corp.

    NT 10-K - GridAI Technologies Corp. (0001604191) (Filer)

    3/31/26 4:05:20 PM ET
    $GRDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form RW filed by GridAI Technologies Corp.

    RW - GridAI Technologies Corp. (0001604191) (Filer)

    3/16/26 9:23:30 PM ET
    $GRDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Borkowski Edward was granted 40,000 shares, increasing direct ownership by 198% to 60,248 units (SEC Form 4)

    4 - GridAI Technologies Corp. (0001604191) (Issuer)

    1/8/26 5:28:29 PM ET
    $GRDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Uppal Manpreet was granted 40,000 shares (SEC Form 4)

    4 - GridAI Technologies Corp. (0001604191) (Issuer)

    1/5/26 5:24:51 PM ET
    $GRDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Pursglove Geordan Garrett was granted 40,000 shares (SEC Form 4)

    4 - GridAI Technologies Corp. (0001604191) (Issuer)

    1/5/26 4:57:27 PM ET
    $GRDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRDX
    Leadership Updates

    Live Leadership Updates

    View All

    GridAI Technologies Corp. Appoints Veteran Energy Executive Tim Healy as Executive Chairman of Grid AI Corp.

    BOCA RATON, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- via IBN – GridAI Technologies Corp. (NASDAQ:GRDX), a technology company focused on intelligent energy orchestration for hyperscale AI data centers, today announced the appointment of Tim Healy as Executive Chairman of the Board of Grid AI Corp., the Company's wholly owned operating subsidiary. Healy brings more than two decades of experience as a founder, CEO, board leader, and investor across the energy technology and energy transition landscape. Over his career, he has founded multiple public companies, establishing a track record of scaling innovative platforms from early commercialization through global deployment and strategic exits

    2/4/26 8:00:00 AM ET
    $GRDX
    Biotechnology: Pharmaceutical Preparations
    Health Care